Anteris Technologies Global Corp.

Compare

41 Followers

AVR Stock Chart & Stats

$5.93

-$0.12(-2.09%)

At close: Jan 08 4:00 PM EST

$5.93

-$0.12(-2.09%)

Day’s Range― - ―

52-Week Range$2.34 - $8.79

Previous Close$5.88

Volume157.53K

Average Volume (3M)238.32K

Market Cap

$158.67M

Enterprise Value$110.67M

Total Cash (Recent Filing)$28.44M

Total Debt (Recent Filing)$2.81M

Price to Earnings (P/E)―

Beta1.93

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.12

Shares Outstanding36,062,370

10 Day Avg. Volume242,674

30 Day Avg. Volume238,319

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.70

Enterprise Value/Revenue44.64

Enterprise Value/Gross Profit75.14

Enterprise Value/Ebitda-1.74

Forecast

1Y Price Target

$17.50

Price Target Upside195.11% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessNew data from the DurAVR Small Aortic Annuli Pooled Cohort demonstrated stellar one-year hemodynamic outcomes as well as safety and efficacy results.

Innovative DesignThe early DurAVR results showcase the promise of the platform's biomimetic design with single-digit gradients, no paravalvular leak, and zero prosthesis–patient mismatch.

Pivotal Trial PreparationPreparations for the PARADIGM pivotal trial accelerated, with 79 sites qualified and global investigator meetings held.

Bears Say

Anteris Technologies Global Corp. News

Anteris Technologies reports clinical outcomes for DurAVR THV in patients

Anteris Technologies (AVR) Global announced one-year clinical outcomes for the DurAVR Transcatheter Heart Valve, or THV, in symptomatic...

3d ago

AVR

Anteris Technologies treats first patient in DurAVR heart valve pivotal trial

Anteris Technologies (AVR) announced the first patients have been enrolled and successfully treated in the DurAVR Transcatheter Heart...

4d ago

AVR

Anteris Technologies to present on one-year outcomes for DurAVR THV

Anteris Technologies (AVR) announced that one-year clinical outcomes with the DurAVR Transcatheter Heart Valve will be presented by...

4d ago

AVR

Anteris receives first European regulatory clearance to commence DurAVR trial

Anteris Technologies (AVR) announced it has received regulatory clearance from the Danish Medicines Agency to initiate the DurAVR...

16d ago

AVR

Promising Investment Opportunity: Anteris Technologies’ DurAVR Platform Showcases Outstanding Clinical Outcomes

TD Cowen analyst Josh Jennings maintained a Buy rating on Anteris Technologies Global Corp. today and set a...

2d ago

AVR

Anteris Technologies Begins Global PARADIGM Trial Enrollment

The latest update is out from Anteris Technologies Global Corp. ( ($AVR) ). On October 27, 2025, Anteris...

3d ago

AVR

Anteris Technologies Raises $11.5M in Stock Offering

Anteris Technologies Global Corp. ( ($AVR) ) just unveiled an update. On October 23, 2025, Anteris Technologies Global...

4d ago

AVR

Anteris Technologies Announces Share Sale Agreement

Anteris Technologies Global Corp. ( ($AVR) ) just unveiled an update. On October 23, 2025, Anteris Technologies Global...

7d ago

AVR

Anteris Technologies Prepares for Annual Stockholder Meeting

Anteris Technologies Global Corp. ( ($AVR) ) has issued an announcement. Anteris Technologies Global Corp. will hold its...

16d ago

AVR

Anteris Technologies Gains European Clearance for Heart Valve Trial

The latest update is out from Anteris Technologies Global Corp. ( ($AVR) ). On October 15, 2025, Anteris...

16d ago

AVR

Anteris Technologies Approves ASX Waiver Proposal

The latest announcement is out from Anteris Technologies Global Corp. ( ($AVR) ). On September 29, 2025, Anteris...

1M ago

AVR

Anteris Technologies Adjourns Special Stockholders Meeting

Anteris Technologies Global Corp. ( ($AVR) ) just unveiled an update. On September 19, 2025, Anteris Technologies Global...

1M ago

AVR

Anteris Technologies Postpones Special Stockholders Meeting

Anteris Technologies Global Corp. ( ($AVR) ) has provided an update. On September 11, 2025, Anteris Technologies Global...

2M ago

AVR

Anteris Technologies announces postponement of special meeting

Anteris Technologies (AVR) Global announced that its Special Meeting of Stockholders, which was originally scheduled to be held...

2M ago

AVR

AVR FAQ

What was Anteris Technologies Global Corp.’s price range in the past 12 months?

Anteris Technologies Global Corp. lowest stock price was $2.34 and its highest was $8.79 in the past 12 months.

What is Anteris Technologies Global Corp.’s market cap?

Anteris Technologies Global Corp.’s market cap is $158.67M.

When is Anteris Technologies Global Corp.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Anteris Technologies Global Corp.’s earnings last quarter?

Anteris Technologies Global Corp. released its earnings results on May 13, 2025. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.491 by -$0.119.

Is Anteris Technologies Global Corp. overvalued?

According to Wall Street analysts Anteris Technologies Global Corp.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Anteris Technologies Global Corp. pay dividends?

Anteris Technologies Global Corp. does not currently pay dividends.

What is Anteris Technologies Global Corp.’s EPS estimate?

Anteris Technologies Global Corp.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Anteris Technologies Global Corp. have?

Anteris Technologies Global Corp. has 36,062,370 shares outstanding.

What happened to Anteris Technologies Global Corp.’s price movement after its last earnings report?

Anteris Technologies Global Corp. reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.491. Following the earnings report the stock price went up 6%.

Which hedge fund is a major shareholder of Anteris Technologies Global Corp.?

Currently, no hedge funds are holding shares in AVR

Anteris Technologies Global Corp. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-615.48%

Trailing 12-Months

Asset Growth

137.36%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Anteris Technologies Global Corp.

Anteris Technologies Global Corp. (AVR) is a biotechnology company focused on developing innovative solutions for cardiovascular disease. The company specializes in the research, development, and commercialization of advanced medical technologies, particularly in the area of heart valve replacements and repair. Anteris leverages its proprietary technologies to create products that aim to improve patient outcomes and enhance the quality of life for individuals suffering from heart conditions.

Anteris Technologies Global Corp. (AVR) Earnings & Revenues

Historic Earnings Reports

AVR Stock 12 Month Forecast

Average Price Target

$17.50

▲(195.11% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","21":"$21","6.75":"$6.75","11.5":"$11.5","16.25":"$16.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,6.75,11.5,16.25,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.25,5.461538461538462,6.673076923076923,7.884615384615384,9.096153846153847,10.307692307692307,11.519230769230768,12.73076923076923,13.942307692307692,15.153846153846153,16.365384615384613,17.576923076923077,18.788461538461537,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.25,5.269230769230769,6.288461538461538,7.3076923076923075,8.326923076923077,9.346153846153847,10.365384615384615,11.384615384615383,12.403846153846153,13.423076923076923,14.442307692307692,15.46153846153846,16.48076923076923,{"y":17.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.25,5.076923076923077,5.903846153846153,6.730769230769231,7.5576923076923075,8.384615384615383,9.211538461538462,10.038461538461538,10.865384615384615,11.692307692307692,12.519230769230768,13.346153846153845,14.173076923076923,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.5,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.5,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.5,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.5,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.5,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.5,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.58,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.58,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.63,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.25,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >